Endpoints
Published October 16, 2026
Lilly wants to study and improve the psychedelic ibogaine, its neuro leader says
Read the full story at Endpoints
Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, following Lilly's $2.8B.
Surfaced by 3 Google Alerts
- Psychedelics
- Ibogaine
- Psychedelic biotech